naltrexone has been researched along with naltrexazone in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carroll-Buatti, M; Hahn, EF; Pasternak, GW | 1 |
| Pasternak, GW | 1 |
| Kearns, KS; Ramsay, EC; Swenson, B | 1 |
| Childs, SE; Ferrell, ST; Radcliffe, RW | 1 |
| Akbari, MR; Dehpour, AR; Homayounfar, H; Mani, AR; Nahavandi, A | 1 |
| Greene, JL; McClean, JM; Smith, MA | 1 |
| Gao, J; Portoghese, PS; Rajamani, R; Sham, YY; Zhang, Y | 1 |
| Akiyama, T; Carstens, E; Carstens, MI; Merrill, AW; Zanotto, K | 1 |
| Freed, WJ; Hayashi, T; Lee, CT; Su, TP; Tsai, SY | 1 |
| Duffy, S; Glanville, JM; Godfrey, C; Hewitt, C; Martyn-St James, M; McCool, R; Neilson, M; Perry, AE | 1 |
| Carson, RE; Henry, S; Huang, Y; Labaree, D; Lin, SF; Nabulsi, N; Naganawa, M; Neumeister, A; Ropchan, J; Tauscher, J; Tomasi, G; Zheng, MQ | 1 |
| Glanville, JM; Godfrey, C; Hewitt, C; Martyn-St James, M; Neilson, M; Perry, AE; Woodhouse, R | 1 |
| Hallgren, KA; Heather, N; Kirouac, M; Maisto, SA; Montes, KS; Pearson, MR; Roos, CR; Wilson, AD; Witkiewitz, K | 1 |
| Henderson-Redmond, AN; Lowe, TE; Morgan, DJ; Tian, XB | 1 |
2 review(s) available for naltrexone and naltrexazone
| Article | Year |
|---|---|
Pharmacological interventions for drug-using offenders.
Topics: Adult; Buprenorphine; Criminals; Female; Heroin; Humans; Male; Methadone; Naltrexone; Narcotics; Randomized Controlled Trials as Topic; Substance-Related Disorders | 2013 |
Pharmacological interventions for drug-using offenders.
Topics: Adult; Buprenorphine; Crime; Criminals; Female; Heroin; Humans; Male; Methadone; Naltrexone; Narcotics; Opiate Substitution Treatment; Randomized Controlled Trials as Topic; Substance-Related Disorders | 2015 |
1 trial(s) available for naltrexone and naltrexazone
| Article | Year |
|---|---|
Kinetic modeling of (11)C-LY2795050, a novel antagonist radiotracer for PET imaging of the kappa opioid receptor in humans.
Topics: Administration, Oral; Adult; Benzamides; Cerebellum; Female; Humans; Kinetics; Male; Middle Aged; Models, Biological; Naltrexone; Positron-Emission Tomography; Pyrrolidines; Radioactive Tracers; Radiography; Receptors, Opioid, kappa | 2014 |
11 other study(ies) available for naltrexone and naltrexazone
| Article | Year |
|---|---|
Irreversible opiate agonists and antagonists: the 14-hydroxydihydromorphinone azines.
Topics: Animals; Brain; Cell Membrane; Dihydromorphine; Drug Stability; Hydromorphone; Kinetics; Naloxone; Naltrexone; Oxymorphone; Receptors, Opioid; Structure-Activity Relationship | 1982 |
Opiate, enkephalin, and endorphin analgesia: relations to a single subpopulation of opiate receptors.
Topics: Analgesia; Animals; Humans; Lethal Dose 50; Morphine; Muridae; Naloxone; Naltrexone; Oxymorphone; Receptors, Opioid; Respiration; Respiratory Insufficiency | 1981 |
Oral induction of anesthesia with droperidol and transmucosal carfentanil citrate in chimpanzees (Pan troglodytes).
Topics: Administration, Oral; Analgesics, Opioid; Anesthetics, Combined; Anesthetics, Dissociative; Animals; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Blood Gas Analysis; Body Temperature; Droperidol; Female; Fentanyl; Heart Rate; Least-Squares Analysis; Male; Mouth Mucosa; Naltrexone; Oximetry; Pan troglodytes; Tiletamine; Zolazepam | 2000 |
Butorphanol and azaperone as a safe alternative for repeated chemical restraint in captive white rhinoceros (Ceratotherium simum).
Topics: Analgesics, Opioid; Anesthetics, Combined; Animals; Azaperone; Butorphanol; Female; Heart Rate; Hypnotics and Sedatives; Immobilization; Injections, Intramuscular; Male; Naltrexone; Oximetry; Perissodactyla | 2000 |
The role of the interaction between endogenous opioids and nitric oxide in the pathophysiology of ethanol-induced gastric damage in cholestatic rats.
Topics: Alcohol Deterrents; Animals; Arginine; Bile Ducts; Cholestasis; Disease Models, Animal; Enzyme Inhibitors; Ethanol; Gastric Mucosa; Ligation; Male; Naltrexone; Narcotic Antagonists; NG-Nitroarginine Methyl Ester; Nitrates; Nitric Oxide; Nitrites; Opioid Peptides; Rats; Stomach Ulcer | 2001 |
Enhanced sensitivity to the antinociceptive effects of kappa opioids in naltrexone-treated rats: dose- and time-dependent effects.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics; Analgesics, Non-Narcotic; Animals; Dose-Response Relationship, Drug; Drug Administration Schedule; Male; Naltrexone; Narcotic Antagonists; Pain; Pain Measurement; Pentazocine; Pyrrolidines; Rats; Rats, Long-Evans; Receptors, Opioid, kappa | 2003 |
Homology modeling and molecular dynamics simulations of the mu opioid receptor in a membrane-aqueous system.
Topics: Animals; Binding Sites; Cattle; Cell Membrane; Computer Simulation; Crystallography, X-Ray; Lipid Metabolism; Lipids; Models, Molecular; Naltrexone; Protein Structure, Tertiary; Receptors, Opioid, mu; Rhodopsin; Sequence Homology; Solvents; Structural Homology, Protein; Water | 2005 |
Scratching behavior and Fos expression in superficial dorsal horn elicited by protease-activated receptor agonists and other itch mediators in mice.
Topics: Animals; Behavior, Animal; Capsaicin; Histamine; Injections, Intradermal; Mice; Morphine; Naltrexone; Oligopeptides; Posterior Horn Cells; Proto-Oncogene Proteins c-fos; Pruritus; Receptor, PAR-2; Receptors, Opioid, mu; Receptors, Proteinase-Activated; Serotonin; Spinal Cord; Tachyphylaxis | 2009 |
Delta opioid peptide DADLE and naltrexone cause cell cycle arrest and differentiation in a CNS neural progenitor cell line.
Topics: Analysis of Variance; Animals; Apoptosis; Cell Cycle; Cell Differentiation; Cell Line; Cell Proliferation; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Interactions; Enkephalin, Leucine-2-Alanine; Flow Cytometry; In Situ Nick-End Labeling; Naltrexone; Neurons; Rats; Stem Cells; Time Factors; Tubulin | 2010 |
Who achieves low risk drinking during alcohol treatment? An analysis of patients in three alcohol clinical trials.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Drinking Behavior; Female; Humans; Male; Naltrexone; Risk; Taurine; Treatment Outcome; United Kingdom; United States | 2017 |
Increased ethanol drinking in "humanized" mice expressing the mu opioid receptor A118G polymorphism are mediated through sex-specific mechanisms.
Topics: Alcohol Drinking; Alleles; Analgesics, Non-Narcotic; Analysis of Variance; Animals; Choice Behavior; Conditioning, Operant; Dose-Response Relationship, Drug; Ethanol; Female; Genotype; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutagenesis, Site-Directed; Naltrexone; Narcotic Antagonists; Polymorphism, Single Nucleotide; Quinine; Receptors, Opioid, mu; Reflex; Reward; Self Administration; Self Stimulation; Sex Characteristics | 2018 |